TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cutia Therapeutics ( (HK:2487) ) has shared an update.
Cutia Therapeutics announced that its Phase III clinical trial results for CU-30101, a localized topical lidocaine and tetracaine cream, were accepted for presentation at the 30th Annual Meeting of the Chinese Society of Dermatology. The trial demonstrated that CU-30101 is as effective as the reference product, Pliaglis®, in providing analgesia with a favorable safety profile, leading to the submission of a marketing authorization application to the National Medical Products Administration.
More about Cutia Therapeutics
Cutia Therapeutics is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry with a focus on dermatology. The company specializes in developing topical anesthesia products, such as the CU-30101 cream, which is aimed at providing localized analgesia for dermatologic procedures.
Average Trading Volume: 1,602,118
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$2.95B
See more insights into 2487 stock on TipRanks’ Stock Analysis page.